Findings may reassure a population already at greater risk.
MedPage Today news story
People with HIV didn’t have a significant rise in depressive symptoms after starting semaglutide (Ozempic, Wegovy, Rybelsus) for diabetes or weight loss, according to a nine-site observational study presented at CROI 2026.
After a median 9.4 months of follow-up, the mean change in depressive symptom scores on the Patient Health Questionnaire-9 was -0.1 (95% CI -0.7 to 0.5) after participants initiated the drug.
People with HIV are already at greater risk of developing depression, anxiety, and cognitive disorders. Neuropsychiatric concerns about GLP-1 drugs were heightened after the FDA’s Adverse Event Reporting System received several reports of suicidal ideation from users in 2023. That safety signal wasn’t seen in any clinical trials or observational studies, however, and the FDA earlier this year asked manufacturers to pull information about risks of suicidal behavior and ideation from drug labels following the agency’s review of evidence.
Read the full news story here.
View all MedPage Today reports from CROI 2026
Source : MedPage Today
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.